Table 2 Participants' characteristics and ART outcome according to the gonadotoxic treatment

Number of participants (n)

38

5

Number of cycles (n)

54

13

Age (years)

33

(29–36.75)

26

(23–40)

0.026

AFC

9

(5–15)

3

(2–4)

< 0.001

Basal FSH (IU/L)

6.1

(5.8–9.2)

10.6

(5.0–16.2)

0.004

AMH (ng/ml)

1.89

(1.15–4.08)

0.29

(0.15–1.04)

0.004

Disease type [n (%)]^a

 Haematological cancers

6

(11.1)

4

(30.8)

 Breast cancer

30

(55.6)

0

(0.0)

 Gynecological cancers

9

(16.7)

0

(0.0)

 Sarcoma

0

(0.0)

4

(30.8)

 Other cancers

7

(13.0)

0

(0.0)

 Systemic autoimmune diseases

2

(3.7)

5

(38.5)

Stimulation start timing/ stimulation phase [n (%)]^b

 Normal (Day 1–4)

23

(42.6)

8

(61.5)

 Random (Follicular phase, Luteal phase)

26

(48.1)

5

(38.5)

 DuoStim

5

(9.3)

0

(0.0)

LH suppression regimen [n (%)]^b

 GnRH antagonist

18

(33.3)

9

(69.2)

 PPOS

15

(27.8)

2

(15.4)

 Others

21

(38.9)

2

(15.4)

Gonadotrophin

 Starting dose of Gonadotropin (IU)

225

(150–300)

150

(150–150)

 < 0.001

 Duration of Gonadotropin use (days)

10

(8–11)

9

(9–16)

0.198

 Total dosage of Gonadotropin use (IU)

2175

(1519–2925)

1350

(1200–1950)

0.026

Triggar [n (%)]^b

 hCG or recombinant hCG

51

(94.4)

13

(100)

 GnRHa

1

(1.9)

0

(0.0)

 Dual triggar

2

(3.7)

0

(0.0)

 Serum estradiol on trigger day (pmol/L)

1334

(795–2099)

835

(438–1035)

0.149

Outcome of oocyte retrieval

 Number of oocyte retrieved (n)

9

(5–14)

3

(1–4)

< 0.001

 Number of MII oocytes retrieved (n)

8

(3–12)

3

(0–4)

0.001

 Number of MI oocytes retrieved (n)

0

(0–1)

0

(0–0)

0.010

 Number of GV oocytes retrieved (n)

0

(0–1)

0

(0–0)

0.018

 Mature oocyte rate (%)^c

90.3

(75.0–100)

100

(77.5–100)

0.039

Method for fertilisation [n (%)]^b

 Conventional insemination

6

(11.1)

0

(0.0)

 Intracytoplasmic sperm injection

10

(18.5)

4

(30.8)

 Split

6

(11.1)

0

(0.0)

 None

32

(59.3)

9

(69.2)

Embryological outcome

 Fertilisation rate (%)^d

76.4

(59.3–100)

N/A

N/A

 Cleavage developmental rate (%)^e

90.0

(59.4–100)

N/A

N/A

 Blastocyst developmental rate (%)^f

87.5

(59.3–100)

N/A

N/A

Vitrified stage [n (%)]^a

 Oocyte

23

(60.5)

4

(80.0)

 Blastocyst

15

(39.5)

1

(20.0)